Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + gefitinib
- Development stage
- Unknown
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of sorafenib (a multikinase inhibitor) and gefitinib (an EGFR tyrosine kinase inhibitor). Sorafenib targets multiple serine/threonine kinases (RAF1, BRAF) and receptor tyrosine kinases (VEGFR, PDGFR, KIT, FLT3, RET), while gefitinib selectively inhibits EGFR tyrosine kinase. This combination has been studied for the treatment of advanced non-small cell lung cancer, showing promising efficacy in clinical trials.
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)EGFR T790M (Epidermal growth factor receptor T790M mutant)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + gefitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + gefitinib.